Revolution Medicines (RVMD)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Precision Oncologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-07. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 10/100 (LOW), 61.2 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 4.98% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- First-Line RAS G12D Pancreatic Cancer Trial Launch Could Be A Game Changer For Revolution Medicines (RVMD)
- Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers
- Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
- Revolution Medicines Seen Having 'Strong' Rasonque Launch in Pancreatic Cancer, UBS Says
- Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
- Is Revolution Medicines (RVMD) Cheap After Its FDA Breakthrough Therapy Win?
- Revolution Medicines (RVMD) Deepens RAS(ON) Bet With Breakthrough PDAC Combo – But Is Risk Repricing?
- Revolution Medicines (RVMD) Wins FDA Breakthrough Status For RASONQUE
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Revolution Medicines.
Full RVMD Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.